71
Participants
Start Date
December 2, 2020
Primary Completion Date
November 14, 2023
Study Completion Date
January 29, 2024
Dupilumab SAR231893
Pharmaceutical form:Injection solution Route of administration: Subcutaneous
Placebo
Pharmaceutical form:Injection solution Route of administration: Subcutaneous
Investigational Site Number : 3480004, Budapest
Investigational Site Number : 0560001, Leuven
Investigational Site Number : 3480001, Pécs
Investigational Site Number : 0560002, Ghent
Investigational Site Number : 7240004, Jerez de la Frontera
Eastern Virginia Medical School (EVMS) Medical Group - Otola Site Number : 8400009, Norfolk
Investigational Site Number : 7240009, Madrid
Investigational Site Number : 7240010, Madrid
Investigational Site Number : 7240005, Madrid / Madrid
Investigational Site Number : 7240008, Pamplona
Investigational Site Number : 7240007, Santander
Investigational Site Number : 7240002, Seville
Optimed Research, LTD Site Number : 8400017, Columbus
Investigational Site Number : 8040005, Dnipro
Investigational Site Number : 8040004, Kharkiv
University of Missouri Health System Site Number : 8400016, Columbia
Nebraska Medical Research Institute Site Number : 8400007, Papillion
Vital Prospects Clinical Research Institute, P.C. Site Number : 8400004, Tulsa
Essential Medical Research, LLC Site Number : 8400014, Tulsa
Pharmaceutical Research & Consulting, Inc. Site Number : 8400006, Dallas
Investigational Site Number : 8040001, Ivano-Frankivsk
Alamo ENT Associates Site Number : 8400021, San Antonio
Colorado Allergy and Asthma Centers, PC Site Number : 8400003, Denver
Bensch Clinical Research LLC Site Number : 8400015, Stockton
Sacramento Ear, Nose & Throat Site Number : 8400010, Roseville
Investigational Site Number : 1560001, Beijing
Investigational Site Number : 6430005, Moscow
Investigational Site Number : 1560005, Changchun
Investigational Site Number : 6430002, Saint Petersburg
Investigational Site Number : 6430003, Saint Petersburg
Investigational Site Number : 1560006, Shanghai
Investigational Site Number : 1560008, Yantai
Investigational Site Number : 6430001, Stavropol
Investigational Site Number : 1560010, Chongqing
Investigational Site Number : 1560013, Changsha
Investigational Site Number : 1520001, Santiago
Investigational Site Number : 0320002, Buenos Aires
Investigational Site Number : 0320003, Ciudad Autonoma Buenos Aires
Investigational Site Number : 0320001, Ciudad Autonoma Buenos Aires
Investigational Site Number : 1240013, Vancouver
Investigational Site Number : 1240010, Hamilton
Investigational Site Number : 1240007, Kingston
Investigational Site Number : 1240016, London
Investigational Site Number : 1240001, Montreal
Investigational Site Number : 1240012, Montreal
Investigational Site Number : 1240002, Trois-Rivières
Investigational Site Number : 1240005, Québec
Investigational Site Number : 1240003, Québec
Investigational Site Number : 6200002, Aveiro
Investigational Site Number : 6200001, Guimarães
Investigational Site Number : 6200003, Matosinhos Municipality
Investigational Site Number : 4100003, Seoul
Investigational Site Number : 4100002, Seoul
Investigational Site Number : 7240001, Barcelona
Investigational Site Number : 7520001, Stockholm
Investigational Site Number : 8040008, Kyiv
Investigational Site Number : 8040002, Kyiv
Investigational Site Number : 8040007, Kyiv
Lead Sponsor
Regeneron Pharmaceuticals
INDUSTRY
Sanofi
INDUSTRY